# Anti-inflammatory Effects of Colchicine in PCI

Study · id `cardio:ct-nct01709981` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01709981](<https://clinicaltrials.gov/study/NCT01709981>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01709981

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 280 participants.

## Technical summary

Registry record NCT01709981. Randomized; quadruple masking; primary purpose treatment. Start 2013-05-30 (actual); primary completion 2019-08-30 (actual). Results posted on 2020-09-09.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 280 participants (enrolled count; ClinicalTrials.gov record NCT01709981, source copy `cardio:ctgov-nct01709981-2022-05-25`, retrieved 2026-10-26)
- Started: 2013-05-30 (actual) (ClinicalTrials.gov record NCT01709981, source copy `cardio:ctgov-nct01709981-2022-05-25`, retrieved 2026-10-26)
- Primary completion: 2019-08-30 (actual) (ClinicalTrials.gov record NCT01709981, source copy `cardio:ctgov-nct01709981-2022-05-25`, retrieved 2026-10-26)
- Completion: 2021-12-13 (actual) (ClinicalTrials.gov record NCT01709981, source copy `cardio:ctgov-nct01709981-2022-05-25`, retrieved 2026-10-26)
- Results first posted: 2020-09-09 (ClinicalTrials.gov record NCT01709981, source copy `cardio:ctgov-nct01709981-2022-05-25`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01709981, source copy `cardio:ctgov-nct01709981-2022-05-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01709981-2022-05-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Anti-inflammatory Effects of Colchicine in PCI
- Condition: Coronary Artery Disease
- Intervention (Drug): Colchicine
- Intervention (Drug): Placebo
- Lead sponsor: NYU Langone Health
- Lead sponsor class: OTHER
- Collaborator: Takeda
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Colchicine (`cardio:colchicine`)
- Registry lists this organization as the lead sponsor: NYU Langone Health (`cardio:org-nyu-langone-health`)
- Registry lists this organization as a collaborator: Takeda (`cardio:org-takeda`)

## Provenance

Content hash: 4e17635fe673b5257b0b44568c9ae7bc0648ad8a49bcb5a85412f139f0ae2255
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
